At a Glance
Your Trusted CDMO Partner
-
Global Clients
100+
-
Employees
4,400+
-
Global Regulatory
Approvals
-
Total Capacity
604KL*
Plant 1
30,000L
Plant 2
154,000L
Plant 3
180,000L
Plant 4
240,000L
* Upon P4 completion in 2023
- Awards
-
By consistently delivering superior client satisfaction through execution excellence and innovation, Samsung Biologics has been selected by our clients for the CDMO Leadership Awards for ten consecutive years.

- CDMO LEADERSHIP AWARDS 2023
-
CDMO LEADERSHIP AWARDS 2023 CAPABILITIES
CDMO LEADERSHIP AWARDS 2023 COMPATIBILITY
CDMO LEADERSHIP AWARDS 2023 EXPERTISE
CDMO LEADERSHIP AWARDS 2023 QUALITY
CDMO LEADERSHIP AWARDS 2023 RELIABILITY
CDMO LEADERSHIP AWARDS 2023 SERVICE
Samsung Biologics received additional recognition as “Champion” in the Capabilities, Compatibility, Quality, and Reliability categories

recognition as “Champion” in the
Capabilities, Compatibility, Quality, and
Reliability categories

CDMO LEADERSHIP AWARDS 2023 CAPABILITIES
CDMO LEADERSHIP AWARDS 2023 COMPATIBILITY
CDMO LEADERSHIP AWARDS 2023 EXPERTISE
CDMO LEADERSHIP AWARDS 2023 QUALITY
CDMO LEADERSHIP AWARDS 2023 RELIABILITY
CDMO LEADERSHIP AWARDS 2023 SERVICE
Global Regulatory Approvals
- 2015
-
FDA : 1
Total : 1
- 2016
-
EMA : 4
FDA : 3
Total : 7
- 2017
-
Others : 4
EMA : 5
FDA : 4
Total : 13
- 2018
-
Others : 8
EMA : 7
FDA : 8
Total : 23
- 2019
-
Others : 37
EMA : 12
FDA : 9
Total : 58
- 2020
-
Others : 63
EMA : 15
FDA : 15
Total : 93
- 2021
-
Others : 98
PMDA : 0
EMA : 19
FDA : 18
Total : 135
- 2022
-
Others : 152
EMA : 25
FDA : 25
Total : 202
- 2023
-
Others : 165
EMA : 26
FDA : 28
Total : 219
Number of Approvals | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|
FDA | 1 | 3 | 4 | 8 | 9 | 15 | 18 | 25 | 28 |
EMA | 4 | 5 | 7 | 12 | 15 | 19 | 25 | 26 | |
Others (PMDA, MFDS, and etc.) |
4 | 8 | 37 | 63 | 98 | 152 | 165 | ||
Cumulative Total | 1 | 7 | 13 | 23 | 58 | 93 | 135 | 202 | 219 |